Search

Your search keyword '"Tapson V"' showing total 263 results

Search Constraints

Start Over You searched for: Author "Tapson V" Remove constraint Author: "Tapson V"
263 results on '"Tapson V"'

Search Results

4. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

5. Treatment effect of selexipag on time to disease progression when initiated early in pulmonary arterial hypertension (PAH) patients: GRIPHON and TRITON pooled analysis

7. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness

8. Remdesivir for the treatment of COVID-19 — Final report

9. Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities

10. Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities

11. The impact of time from diagnosis at baseline on long-term outcome in the GRIPHON Study: Selexipag in pulmonary arterial hypertension (PAH)

12. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness

17. Management appropriateness and outcomes of patients with acute pulmonary embolism

18. THE IMPACT OF TIME FROM DIAGNOSIS AT BASELINE ON LONG-TERM OUTCOME IN THE GRIPHON STUDY: SELEXIPAG IN PULMONARY ARTERIAL HYPERTENSION (PAH)

19. 4973Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities

21. The Impact of Time from Diagnosis at Baseline on Long-Term Outcome in the GRIPHON Study: Selexipag in Pulmonary Arterial Hypertension

24. S122 Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension

27. Pulmonary arterial hypertension-related morbidity is prognostic for survival: Insights from the SERAPHIN and GRIPHON studies

30. Cibler la voie de la prostacycline dans le traitement des HTAP associées aux connectivites : expérience de Griphon – étude contrôlée, randomisée avec le selexipag

31. Prognostic significance of tricuspid annular displacement in normotensive patients with acute symptomatic pulmonary embolism

32. SELEXIPAG FOR PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE (PAH-CHD) AFTER DEFECT CORRECTION: INSIGHTS FROM THE RANDOMISED CONTROLLED GRIPHON STUDY

33. Effekt von Selexipag auf den primären kombinierten Morbiditäts- und Mortalitätsendpunkt in Abhängigkeit von vorbestehenden PAH-Therapien, Ätiologie, Alter und geographischer Region: Ergebnisse der GRIPHON Studie

34. Controversies in diagnosis of pulmonary embolism

35. Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study

39. Opinions and research priorities.

45. Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease

49. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006

Catalog

Books, media, physical & digital resources